Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
April 4, 2005
- Chugai's Actemra, Actelion's Tracleer to Be Approved in April
April 4, 2005
- Asahi Kasei Pharma to Earnestly Seek Licensing, M&As
March 28, 2005
- JPA Prepares Q&A on Personal Info. Protection Law for Pharmacies
March 28, 2005
- Dr Aoki of JPMA Calls For Speedier Approval
March 28, 2005
- JMA Compiles Booklet on Protection of Personal Information
March 28, 2005
- JPMA Approves Activities Plan for FY2005
March 28, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 28, 2005
- FPMAJ Approves Activities Plan for FY2005
March 28, 2005
- Data Show Reduced Cardiovascular Events with High Doses of Lipitor
March 28, 2005
- Nichi-iko Aims to Become Top GE Company in 2005
March 28, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 28, 2005
- Mediceo HD to Cut Costs Further
March 28, 2005
- PRESS SEMINAR
March 28, 2005
- Bio Science to Advance into China through Tie-up with Choseido
March 28, 2005
- OTC NEWS IN BRIEF
March 28, 2005
- Choseido Aims at Sales of \10 Bil. in 2007
March 28, 2005
- BUSINESS NEWS IN BRIEF
March 28, 2005
- NEW PRODUCTS
March 28, 2005
- PMDA to Beef Up Review Team
March 28, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…